Ranbaxy Laboratories Ltd.- (Amalgamation) Stock Analysis

BSE: 500359 | NSE: RANBAXY | Pharmaceuticals & Drugs | Mid Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on Ranbaxy Labs.

M-Cap below 100cr DeciZen not available

Ranbaxy Labs. Price Chart

P/E Ratio (SA):
Market Cap:
36,602.8 Cr.
52-wk low:
52-wk high:
Bole Toh?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Ranbaxy Labs.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

ROCE % 21.5%6.8%10.3%5.2%3.5%4.4%10.7%-0.9%6.3%-2.6%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3,7203,5654,0304,1364,4704,7805,6707,7996,3045,4925,571
YoY Gr. Rt. %--4.2%13%2.6%8.1%6.9%18.6%37.6%-19.2%-12.9%-
Adj EPS 14.2511.
YoY Gr. Rt. %--64.7%124.1%-44.6%-49%124.2%189.2%-132.1%NA-324.3%-
BVPS (₹) 67.263.662.867.884.194121.645.344.920.31.5
Adj Net Profit 529187420233134300868-279201-451-136
Cash Flow from Ops. 411107315686-390-6651,169128662-974-
Debt/CF from Ops. 0.39.610.15.1-9.5-53.733.87.3-5.1-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 4.4%4.2%-1.1%-12.9%
Adj EPS -196.8%-227.3%-180.2%-324.3%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 21.97.717.
Op. Profit Mgn %
Net Profit Mgn % 14.25.310.45.636.315.3-3.63.2-8.2-2.4
Debt to Equity
Working Cap Days 2222212052222382812962994113750
Cash Conv. Cycle 7798105116101105931071751070

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Ranbaxy Laboratories Ltd.- (Amalgamation)

Standalone Consolidated
TTM EPS (₹) -3.2 -19.1
TTM Sales (₹ Cr.) 5,571 10,614
BVPS (₹.) 1.5 59.8
Reserves (₹ Cr.) -148 2,334
P/BV 561.84 14.37
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 810.30 / 869.00
All Time Low / High (₹) 29.17 / 869.00
Market Cap (₹ Cr.) 36,603
Equity (₹ Cr.) 212.8
Face Value (₹) 5
Industry PE 42.8

Management X-Ray of Ranbaxy Labs. :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Ranbaxy Labs.

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Ranbaxy Laboratories Ltd.- (Amalgamation) FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Ranbaxy Labs. on 01-Jan-1970 05:30 is : 0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Ranbaxy Labs. stood at ₹ 36,602.8.
The latest PE ratio of Ranbaxy Labs. as of 01-Jan-1970 05:30 is 0.00.
The latest PB ratio of Ranbaxy Labs. as of 01-Jan-1970 05:30 is 561.8
The 52-week high of Ranbaxy Labs. is ₹ 869.0 and the 52-week low is ₹ 810.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Ranbaxy Labs. is ₹ 5,571 ( Cr.) .

About Ranbaxy Laboratories Ltd.- (Amalgamation)

Ranbaxy Laboratories, is India's largest pharmaceutical company incorporated in 1961. The company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries.  Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Ranbaxy has its R & D centre that helps company to have long term competitive advantage. It caters treatment to segment of diseases that includes Cardiovascular, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology.

Ranbaxy's top 20 products, ranging from Anti-infectives to Dermatological, account for revenues of over $600 Million. Using the finest R&D and Manufacturing facilities, that manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, Active Pharmaceuticals and intermediates (API).

In 2001 Ranbaxy entered consumer healthcare through launch of 4 brands Revital, Pepfiz, Gesdyp & Garlic Pearls.

In 2004 launched its first herbal range of products through New Age Herbals (NAH), with products offering remedies in categories of Cough & Cold (Olesan Oil & Cough Syrups) and Appetite Stimulant (Eat Ease).

In 2005, another popular brand, Chericof - The complete cough formula was introduced. During 2006, the business registered sales of $19 Million registering a growth of 19%. Revital, the flagship brand continues to maintain leadership in its segment.

It also produces molecules like Simvastatin, Ciprofloxacin, Amoxycillin, Isotretinon and many more

In April 2014 Sun Pharmaceutical Industries Ltd and Ranbaxy Laboratories Ltd announced that they have entered into definitive agreements pursuant to which Sun Pharma will acquire 100% of Ranbaxy in an all-stock transaction. Under these agreements, Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. This exchange ratio represents an implied value of Rs 457 for each Ranbaxy share, a premium of 18% to Ranbaxy’s 30-day volume-weighted average share price and a premium of 24.3% to Ranbaxy’s 60-day volume-weighted average share price, in each case, as of the close of business on April 4, 2014.

Milestone achieved

• 2013 -Ranbaxy wins the ASSOCHAM Innovation Excellence Platinum Award for SynriamTM, a new age cure for malaria

• 2012 - Ranbaxy wins the 2012 Frost & Sullivan Malaysia Excellence Award for being adjudged the Malaysian Pharmaceutical Company of the Year in the Generics Drug Category

•2012 Launch India's first New Chemical Entity (NCE), SynriamTM, a new age cure for Malaria

• 2011  Launch Atorvastatin, a generic version of the world’s largest selling cholesterol lowering drug, in the US with 180-day market exclusivity

• 2011 - Ranbaxy is felicitated with the New Jersey Business and Industry Association Award for Excellence in the Business Expansion Category

• 2010 - Ranbaxy enters the Golden jublee year

• 2010- For the first time Ranbaxy delivered quarterly sales of over $500 million

• 2010  Launch First-to-File (FTF) product Donepezil hydrochloride tablets 5 mg and 10 mg with 180-day market exclusivity in the US Healthcare System

• 2009- Dailchi Sankyo and Ranbaxy announced reconstitution of Ranbaxy executive leadership. Ranbaxy was acquired by Daiichi Sankyo through acquisition of it 52.5% of the equity share capital.

• 2008- Ranbaxy partnered with Daiichi Sankyo Company to create a strategic combination of an innovator and generic powerhouse

• 2007- Ranbaxy has signed new R&D agreement with GSK

• 2006-Ranbaxy acquires generic unbranded business of GSK in Italy & Spain

• 2006 -Ranbaxy acquires Terapia largest independent generic pharma company in Romania for $ 324 million

• 2003 Ranbaxy receives The Economic Times award for corporate excellence for ‘The Company of the year’2002-03

• 2000 Ranbaxy acquires Bayers generic business in Germany. It has alliance with Glaxo SmithKline for Drug discovery & clinical development

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now